Duchenne muscular dystrophy

Area of Science:

• Genetics and Molecular Biology
• Pediatric Neurology
• Rare Diseases

Background:

• Duchenne muscular dystrophy (DMD) is the most prevalent childhood X-linked muscular dystrophy.
• Characterized by proximal muscle weakness and calf hypertrophy, DMD typically leads to wheelchair dependence by age 12.
• Cardiorespiratory complications are the primary cause of mortality, usually in the late teens to early twenties.

Purpose of the Study:

• To review the clinical features, diagnostic investigations, and current management strategies for Duchenne muscular dystrophy.
• To provide an overview of recent advancements and novel therapeutic approaches for DMD.
• To highlight the ongoing efforts towards finding a definitive cure for this debilitating genetic disorder.

Main Methods:

• Literature review of clinical features, investigations, and management of DMD.
• Analysis of current treatment modalities, including corticosteroids and respiratory support.
• Exploration of emerging novel therapies and research directions for Duchenne muscular dystrophy.

Main Results:

• Current management, including corticosteroids and ventilation, has improved function, ambulation, quality of life, and life expectancy in DMD patients.
• Despite advances, DMD remains a devastating disorder with significant morbidity and mortality.
• Novel therapies are under investigation with the aim of providing a cure for Duchenne muscular dystrophy.

Conclusions:

• Duchenne muscular dystrophy requires comprehensive management focusing on symptom control and supportive care.
• Ongoing research into novel therapies offers hope for more effective treatments and potential cures.
• Continued investigation into the pathophysiology and therapeutic targets of DMD is crucial for improving patient outcomes.